These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26144897)

  • 1. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review.
    Jit M; Mibei W
    Vaccine; 2015 Jul; 33(32):3788-94. PubMed ID: 26144897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On discounting of health gains from human papillomavirus vaccination: effects of different approaches.
    Westra TA; Parouty M; Brouwer WB; Beutels PH; Rogoza RM; Rozenbaum MH; Daemen T; Wilschut JC; Boersma C; Postma MJ
    Value Health; 2012 May; 15(3):562-7. PubMed ID: 22583467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuing vaccines: deficiencies and remedies.
    Bloom DE
    Vaccine; 2015 Jun; 33 Suppl 2():B29-33. PubMed ID: 26022563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WHO Guide for standardisation of economic evaluations of immunization programmes.
    Walker DG; Hutubessy R; Beutels P
    Vaccine; 2010 Mar; 28(11):2356-9. PubMed ID: 19567247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness.
    Luyten J; Beutels P
    Health Aff (Millwood); 2016 Feb; 35(2):212-8. PubMed ID: 26858372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
    Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
    Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective.
    Ho AM; Nelson EA; Walker DG
    Arch Dis Child; 2008 Jan; 93(1):52-8. PubMed ID: 17855438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discounting health effects in pharmacoeconomic evaluations: current controversies.
    Bos JM; Postma MJ; Annemans L
    Pharmacoeconomics; 2005; 23(7):639-49. PubMed ID: 16173156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim.
    Megiddo I; Colson AR; Nandi A; Chatterjee S; Prinja S; Khera A; Laxminarayan R
    Vaccine; 2014 Aug; 32 Suppl 1():A151-61. PubMed ID: 25091670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social welfare and adolescent vaccination programs in the United States: the economic opportunities for a systematic expansion.
    Vernon JA; Payette M; Chatterjee A
    Soc Work Public Health; 2009; 24(5):414-45. PubMed ID: 19731186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
    Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
    Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses.
    Newall AT; Reyes JF; Wood JG; McIntyre P; Menzies R; Beutels P
    Vaccine; 2014 Feb; 32(7):759-65. PubMed ID: 24295806
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.